Menicon Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3921270009
JPY
1,700.00
44 (2.66%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

186.3 k

Shareholding (Jun 2024)

FII

0.22%

Held by 1 FIIs

DII

99.78%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROCE of 12.03%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 22.66

 
3

With a growth in Net Profit of 47.83%, the company declared Very Positive results in Dec 25

4

With ROCE of 8.92%, it has a very attractive valuation with a 0.93 Enterprise value to Capital Employed

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JPY 123,579 Million (Small Cap)

stock-summary
P/E

12.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.41

stock-summary
Return on Equity

6.04%

stock-summary
Price to Book

1.43

Revenue and Profits:
Net Sales:
32,452 Million
(Quarterly Results - Dec 2025)
Net Profit:
3,197 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.56%
0%
8.56%
6 Months
47.7%
0%
47.7%
1 Year
28.89%
0%
28.89%
2 Years
2.75%
0%
2.75%
3 Years
-37.8%
0%
-37.8%
4 Years
-42.2%
0%
-42.2%
5 Years
-44.54%
0%
-44.54%

Menicon Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
7.53%
EBIT Growth (5y)
7.40%
EBIT to Interest (avg)
22.66
Debt to EBITDA (avg)
0.65
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.77
Tax Ratio
39.68%
Dividend Payout Ratio
37.83%
Pledged Shares
0
Institutional Holding
0.22%
ROCE (avg)
12.03%
ROE (avg)
8.66%

Valuation key factors

Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
0.91
EV to EBIT
10.47
EV to EBITDA
5.69
EV to Capital Employed
0.93
EV to Sales
0.87
PEG Ratio
1.04
Dividend Yield
NA
ROCE (Latest)
8.92%
ROE (Latest)
7.35%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.22%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 3.92% vs 3.23% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 47.87% vs 117.94% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32,452.00",
          "val2": "31,229.00",
          "chgp": "3.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6,513.00",
          "val2": "5,641.00",
          "chgp": "15.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "206.00",
          "val2": "205.00",
          "chgp": "0.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3,197.00",
          "val2": "2,162.00",
          "chgp": "47.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "118.10%",
          "val2": "102.70%",
          "chgp": "1.54%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 4.56% vs 5.44% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 23.85% vs -38.47% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "121,491.00",
          "val2": "116,192.00",
          "chgp": "4.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18,502.00",
          "val2": "16,900.00",
          "chgp": "9.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "751.00",
          "val2": "672.00",
          "chgp": "11.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-175.00",
          "val2": "-1,112.00",
          "chgp": "84.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "5,624.00",
          "val2": "4,541.00",
          "chgp": "23.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "82.70%",
          "val2": "77.10%",
          "chgp": "0.56%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
32,452.00
31,229.00
3.92%
Operating Profit (PBDIT) excl Other Income
6,513.00
5,641.00
15.46%
Interest
206.00
205.00
0.49%
Exceptional Items
0.00
0.00
Consolidate Net Profit
3,197.00
2,162.00
47.87%
Operating Profit Margin (Excl OI)
118.10%
102.70%
1.54%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 3.92% vs 3.23% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 47.87% vs 117.94% in Sep 2025

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
121,491.00
116,192.00
4.56%
Operating Profit (PBDIT) excl Other Income
18,502.00
16,900.00
9.48%
Interest
751.00
672.00
11.76%
Exceptional Items
-175.00
-1,112.00
84.26%
Consolidate Net Profit
5,624.00
4,541.00
23.85%
Operating Profit Margin (Excl OI)
82.70%
77.10%
0.56%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 4.56% vs 5.44% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 23.85% vs -38.47% in Mar 2024

stock-summaryCompany CV
About Menicon Co., Ltd. stock-summary
stock-summary
Menicon Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available